Cambridge Investment Research Advisors, Inc. Xeris Biopharma Holdings, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.9 Billion
- Q4 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 34,542 shares of XERS stock, worth $129,532. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,542
Previous 34,542
-0.0%
Holding current value
$129,532
Previous $98,000
19.39%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding XERS
# of Institutions
163Shares Held
61.5MCall Options Held
34.2KPut Options Held
21.7K-
Black Rock Inc. New York, NY10.3MShares$38.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.9MShares$29.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.35MShares$12.6 Million0.0% of portfolio
-
State Street Corp Boston, MA3.34MShares$12.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.88MShares$10.8 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $510M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...